详情页 - 广东省中医院知识库

当前位置：首页 > 详情页

The role of m6A-mediated PD-1/PD-L1 in antitumor immunity

11| 认领 | 导出 | 链接全文 |

文献详情

资源类型：

WOS体系：

Pubmed体系：

收录情况： ◇ SCIE

作者：

机构： [1]The First Affiliated Hospital, Department of Clinical Laboratory Medicine, Institution of Microbiology and Infectious Diseases, Hengyang Medical School, University of South China, Hengyang, 421001 Hunan, China [2]Hunan Province Key Laboratory of Basic and Applied Hematology, Molecular Biology Research Center & Center for Medical Genetics, School of Life Sciences, Central South University, Changsha, 410078 Hunan, China [3]Department of Dermatology, Hunan Key Laboratory of Skin Cancer and Psoriasis, Hunan Engineering Research Center of Skin Health and Disease, Xiangya Clinical Research Center for Cancer Immunotherapy, Xiangya Hospital, Central South University, Changsha, Hunan 410008, China [4]Department of Urology Surgery, Shenzhen Traditional Chinese Medicine Hospital, Shenzhen, 518033 Guangdong, China [5]The Affiliated Nanhua Hospital, Department of Clinical Laboratory, Hengyang Medical School, University of South China, Hengyang, 421002 Hunan, China

出处：

DOI：

ISSN：

摘要：

N6-methyladenosine (m6A) is the most prevalent, abundant and conserved type of internal posttranscriptional RNA modification in eukaryotic cells. Emerging evidence suggests that m6A modifications perform important functions that affect antitumor immunity. Programmed death 1 (PD-1) and programmed cell death-ligand 1 (PD-L1) are the two most well-studied immune checkpoint pathways. The interaction of PD-L1 with its receptor PD-1 inhibits cytotoxic T-cell-mediated tumor responses, and blockade of this interaction has proven to be an effective immunotherapy strategy in various cancers. Unfortunately, few cancer patients benefit from the two tools due to uncertain resistance. m6A plays an important role in affecting RNA biogenesis and process in various cancers. Understanding the molecular mechanism of drug resistance will promote the development of personalized clinical management. In this review, we systematically discussed the mechanisms by which m6A regulates PD-1 and PD-L1 expression and further their functions in the process of tumor immunotherapy and the potential application prospects of m6A-associated molecules. Moreover, mounting m6Ascore is established to evaluate the prognosis of cancer.Copyright © 2023 Elsevier Inc. All rights reserved.

基金：

语种：

WOS：

PubmedID：

中科院(CAS)分区：

出版当年[2022]版：

大类 | 2 区

医学

小类 | 2 区药学

最新[2025]版：

大类 | 2 区医学

小类 | 2 区药学

JCR分区：

出版当年[2021]版：

Q1 PHARMACOLOGY & PHARMACY

最新[2023]版：

Q1 PHARMACOLOGY & PHARMACY

影响因子： 5.3 最新[2023版] 5.2 最新五年平均 6.1 出版当年[2021版] 6.194 出版当年五年平均 5.858 出版前一年[2020版] 5.8 出版后一年[2022版]

第一作者：

第一作者机构： [1]The First Affiliated Hospital, Department of Clinical Laboratory Medicine, Institution of Microbiology and Infectious Diseases, Hengyang Medical School, University of South China, Hengyang, 421001 Hunan, China

通讯作者：

通讯机构： [1]The First Affiliated Hospital, Department of Clinical Laboratory Medicine, Institution of Microbiology and Infectious Diseases, Hengyang Medical School, University of South China, Hengyang, 421001 Hunan, China [3]Department of Dermatology, Hunan Key Laboratory of Skin Cancer and Psoriasis, Hunan Engineering Research Center of Skin Health and Disease, Xiangya Clinical Research Center for Cancer Immunotherapy, Xiangya Hospital, Central South University, Changsha, Hunan 410008, China [4]Department of Urology Surgery, Shenzhen Traditional Chinese Medicine Hospital, Shenzhen, 518033 Guangdong, China [5]The Affiliated Nanhua Hospital, Department of Clinical Laboratory, Hengyang Medical School, University of South China, Hengyang, 421002 Hunan, China [*1]Department of Clinical Laboratory Medicine, Institution of Microbiology and Infectious Diseases, The First Affiliated Hospital of University of South China, Hengyang, Hunan, China

推荐引用方式(GB/T 7714)：

APA：

MLA：